Immune Globulin Subcutaneous (Human) (Octapharma)
- Generic Name
- Immune Globulin Subcutaneous (Human) (Octapharma)
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
Recruiting
- Conditions
- Primary Immunodeficiency Diseases (PID)
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 100
- Registration Number
- NCT05986734
- Locations
- 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 64
- Registration Number
- NCT03939533
- Locations
- 🇺🇸
Octapharma Research Site, Bellingham, Washington, United States
Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 1
- Registration Number
- NCT03686969
- Locations
- 🇷🇺
I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY Rheumatology Department Of, Clinici Of Nephrology, Moscow, Russian Federation
Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 60
- Registration Number
- NCT03656640
- Locations
- 🇲🇶
CHU de la Martinique- Hopital Pierre Zobda Quitman, Fort-de-France, Martinique
🇫🇷Chu de Rouen - Bois Guillaume, Rouen, France
🇫🇷APHP - Pitie Salpetriere, Paris, France
The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency
Completed
- Conditions
- Secondary Immune Deficiency
- Interventions
- Drug: Other Subcutaneous Immunoglobulins
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 102
- Registration Number
- NCT03369301
- Locations
- 🇫🇷
CH William Morey Chalon-sur-Saône, Chalon-sur-Saône, France
🇫🇷CHD Vendée, La Roche-sur-Yon, France
🇫🇷CH Orléans, Orléans, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath